Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALV-306
- Development stage
- Discontinued
- Lead developer
- PureTech
01
Overview
ALV-306 is an investigational pharmaceutical candidate originally developed by Alivio Therapeutics for the treatment of pouchitis and related inflammatory bowel conditions. Publicly available pipeline data list ALV-306 as a discontinued program and do not disclose its molecular modality, specific target, or detailed mechanism of action, beyond its positioning within gastrointestinal and inflammatory indications. As such, the precise pharmacologic class, target engagement, and route of administration of ALV-306 have not been clearly characterized in accessible sources, and the asset appears to have been terminated prior to late-stage clinical development.[5]
Beyond the preview
Go deeper on ALV-306.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALV-306.